A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9799-9808

  Rokavec, Matjaž ^a,c,e   Schroth, Werner ^a,c   Amaral, Sandra M C ^a,c,f   Fritz, Peter ^a,c   Antoniadou, Lydia ^a,c   Glavač, Damjan ^e   Simon, Wolfgang ^b   Schwab, Matthias ^a,c,d   Eichelbaum, Michel ^a,c   Brauch, Hiltrud ^a,c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

^f NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 2D6; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; MESSENGER RNA; RAS PROTEIN; TAMOXIFEN; TC21 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; DNA, NEOPLASM; ELECTROPHORESIS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; POLYMORPHISM, GENETIC; RNA, MESSENGER; TAMOXIFEN;

EID: 57149102096     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0247     Document Type: Article

References (47)

1. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008;44:30-8.
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
3. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58.
4. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003;2:205-13.
5. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25:5815-24.
6. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75.
7. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151-9.
8. Buck MB, Coller JK, Murdter TE, Eichelbaum M, Knabbe C. TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Res Treat 2008;107:15-24.
9. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
10. Coller JK, Krebsfaenger N, Klein K, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002;54:157-67.
11. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002;30:869-74.
12. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93.
13. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
14. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21.
15. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003;12:362-7.
16. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-6S.
17. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 2007;13:1950-4.
18. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447-54S.
19. Berstein LM, Zheng H, Yue W, et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 2003;10:267-77.
20. Yu Y, Feig LA. Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells. Oncogene 2002;21:7557-68.
21. Bos JL. Ras-like GTPases. Biochim Biophys Acta 1997;1333:M19-31.
22. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
23. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-413.
24. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993;62:851-91.
25. Barker KT, Crompton MR. Ras-related TC21 is activated by mutation in a breast cancer cell line, but infrequently in breast carcinomas in vivo. Br J Cancer 1998;78:296-300.
26. Huang Y, Saez R, Chao L, Santos E, Aaronson SA, Chan AM. A novel insertional mutation in the TC21 gene activates its transforming activity in a human leiomyosarcoma cell line. Oncogene 1995;11:1255-60.
27. Chan AM, Miki T, Meyers KA, Aaronson SA. A human oncogene of the RAS superfamily unmasked by expression cDNA cloning. Proc Natl Acad Sci U S A 1994;91:7558-62.
28. Graham SM, Cox AD, Drivas G, Rush MG, D'Eustachio P, Der CJ. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol Cell Biol 1994;14:4108-15.
29. Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 1996;12:169-76.
30. Rong R, He Q, Liu Y, Sheikh MS, Huang Y. TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-κB signaling pathway. Oncogene 2002;21:1062-70.
31. Murphy GA, Graham SM, Morita S, et al. Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation. J Biol Chem 2002;277:9966-75.
32. Erdogan M, Pozzi A, Bhowmick N, Moses HL, Zent R. Signaling pathways regulating TC21-induced tumorigenesis. J Biol Chem 2007;282:27713-20.
33. Rosario M, Paterson HF, Marshall CJ. Activation of the Ral and phosphatidylinositol 3′ kinase signaling pathways by the ras-related protein TC21. Mol Cell Biol 2001;21:3750-62.
34. Graham SM, Vojtek AB, Huff SY, et al. TC21 causes transformation by Raf-independent signaling pathways. Mol Cell Biol 1996;16:6132-40.
35. Movilla N, Crespo P, Bustelo XR. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins. Oncogene 1999;18:5860-9.
36. Rosario M, Paterson HF, Marshall CJ. Activation of the Raf/MAP kinase cascade by the Ras-related protein TC21 is required for the TC21-mediated transformation of NIH 3T3 cells. EMBO J 1999;18:1270-9.
37. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
38. Rokavec M, Justenhoven C, Schroth W, et al. A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk. Clin Cancer Res 2007;13:7506-14.
39. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005;42:97-108.
40. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
41. Jaremko M, Justenhoven C, Abraham BK, et al. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat 2005;25:232-8.
42. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;6:607-16.
43. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
44. Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003;278:2701-12.
45. Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 2002;277:50768-75.
46. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
47. Brauch H, Schroth W, Eichelbaum M, Schwab M, Harbeck N. Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer. Breast Care 2008;3:43-50.